glp 1 agonist meds GLP-1 Receptor Agonists: The New Wave in Diabetes Management GLP-1: Genetic Variants Related to

As mentioned above, 70% of diabetes patients discontinue GLP-1 treatment within two years

Risks include gastrointestinal side effects, pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors

GLP-1/GIP medications do not: reduce central pain amplification correct nervous-system hypersensitivity treat neuropathic pain reverse joint degeneration Some patients feel better simply because weight loss improves sleep, mobility, energy, and moodnot because the medication treats fibromyalgia biology

Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity

According to the World Health Organization (WHO), the global prevalence of obesity has nearly tripled since 1975